Quantiphi Strengthens AI Drug Discovery Development Collaboration
AI-First Company Quantiphi Partners with Transcell
Strategic Minority Investment to Enhance Drug Discovery Process
Palo Alto, CA - August 22, 2023 - Quantiphi, a leading AI-first digital engineering company, today announced a strategic collaboration with Transcell, a biotechnology company focused on harnessing the power of artificial intelligence (AI) for drug discovery and development. This collaboration includes a strategic minority investment from Quantiphi in Transcell.
The partnership aims to leverage Quantiphi's expertise in AI and digital engineering to enhance Transcell's drug discovery and development capabilities. By combining Quantiphi's AI-driven platforms and methodologies with Transcell's proprietary drug discovery technologies, the collaboration seeks to accelerate the identification, validation, and optimization of novel drug candidates.
This collaboration is a significant step forward in the field of AI-powered drug discovery. AI offers tremendous potential for transforming drug discovery by enabling more efficient identification of effective drug compounds, reducing the time and costs associated with drug development.
Quantiphi and Transcell's partnership is poised to make significant contributions to the healthcare industry, bringing new and innovative treatments to patients faster and more efficiently.
Comments